Who is sponsoring NCT05160714?

NCT05160714 is sponsored by University Hospital Tuebingen.

What drugs are being tested in NCT05160714?

Interventions in NCT05160714: Real-time ADC-guided response adaptive Boost in HNC.

What condition does NCT05160714 study?

NCT05160714 studies Head and Neck Cancer.

Is NCT05160714 still recruiting?

NCT05160714 is currently status unknown. Last updated 1 February 2022.

Last reviewed 2022-02-01 · How we verify

NCT05160714: MRL-02

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Individualized Response-adaptive Radiation Dose Prescription in HNC Based on MRI

Status unknown Phase 1 Last updated 1 February 2022

What this trial tests

Phase 1 trial testing Real-time ADC-guided response adaptive Boost in HNC in Head and Neck Cancer in 24 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
30 March 2023

30 March 2025

Quick facts

Lead sponsor	University Hospital Tuebingen
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 January 2022
Primary completion	30 March 2023
Estimated completion	30 March 2025
Sites	1 location across Germany

Drugs / interventions tested

Real-time ADC-guided response adaptive Boost in HNC

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

University Hospital Tuebingen

Who can join

18 and older, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 1 dose-finding study investigates the maximal tolerated dose for a subsequent phase 2 trial testing MR-guided individualized response-adaptive dose prescription in HNC.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

MRI for biology-guided radiation therapy: Are we there yet? A summary of the 2024 ISMRM member-initiated session.
Tadimalla S, Deng J, Barker PB, Shim H, et al · · 2025 · cited 1× · PMID 40554724 · DOI 10.1002/mrm.30616
Abstracts DEGRO 2022
· 2022

Verify or expand the search:

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other University Hospital Tuebingen trials

Trials by the same sponsor.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05160714 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
Last refreshed: 1 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05160714.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing